Molecule Details
| InChIKey | JYYLVUFNAHSSFE-UHFFFAOYSA-N |
|---|---|
| Compound Name | Pamapimod |
| Canonical SMILES | Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 9 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.14 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB19169 |
|---|---|
| Drug Name | Pamapimod |
| CAS Number | 449811-01-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Pamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2). |
Categories: Pyridines p38 Mitogen-Activated Protein Kinases, antagonists & inhibitors
Cross-references: BindingDB: 50314070 ChEBI: 90685 CHEMBL1090089 ChemSpider: 17347490 PDB: FLW Wikipedia: Pamapimod ZINC: ZINC000030691792
Target Activities (9)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| Q16539 | MAPK14 | Homo sapiens | Human | PF00069 | 8.4 | IC50 | ChEMBL;BindingDB |
| P45984 | MAPK9 | Homo sapiens | Human | PF00069 | 7.8 | Kd | ChEMBL;BindingDB |
| P53779 | MAPK10 | Homo sapiens | Human | PF00069 | 7.7 | Kd | ChEMBL;BindingDB |
| Q15759 | MAPK11 | Homo sapiens | Human | PF00069 | 6.9 | Kd | ChEMBL;BindingDB |
| O75676 | RPS6KA4 | Homo sapiens | Human | PF00069 PF00433 | 6.8 | Kd | ChEMBL;BindingDB |
| Q9UBE8 | NLK | Homo sapiens | Human | PF00069 | 6.8 | Kd | ChEMBL;BindingDB |
| P45983 | MAPK8 | Homo sapiens | Human | PF00069 | 6.7 | Kd | ChEMBL;BindingDB |
| P49674 | CSNK1E | Homo sapiens | Human | PF00069 | 6.6 | Kd | ChEMBL;BindingDB |
| P51812 | RPS6KA3 | Homo sapiens | Human | PF00069 PF00433 | 6.5 | Kd | ChEMBL;BindingDB |
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | inhibitor | targets |